Effect of the Friendship Bench Intervention on Antiretroviral Therapy Outcomes and Mental Health Symptoms in Rural Zimbabwe: A Cluster Randomized Trial.


Journal

JAMA network open
ISSN: 2574-3805
Titre abrégé: JAMA Netw Open
Pays: United States
ID NLM: 101729235

Informations de publication

Date de publication:
03 Jul 2023
Historique:
medline: 17 7 2023
pubmed: 13 7 2023
entrez: 13 7 2023
Statut: epublish

Résumé

Common mental disorders (CMD), which include depression and anxiety, are prevalent among people living with HIV and are associated with suboptimal antiretroviral therapy (ART) adherence. To assess the effect of a lay health worker-led psychological intervention on ART adherence, virologic suppression, and mental health symptoms. Open-label pragmatic cluster trial with 1:1 block randomization of 16 health facilities in rural Bikita, Zimbabwe. Recruitment occurred from October 2018 to December 2019, and participants were followed up for 12 months, ending in December 2020. Participants were adults aged 18 years and older, who spoke English or Shona, screened positive for CMD (Shona Symptoms Questionnaire [SSQ]-14 score ≥9), received first-line ART for 6 or more months, had no World Health Organization stage 4 disease, no psychosis, were not pregnant, and provided informed consent. Data were analyzed from March 2021 to February 2022. The Friendship Bench, consisting of 6 lay health worker-led weekly problem-solving therapy sessions and optional peer-led group support. The primary outcome was mean adherence during 2 to 6 months of follow-up, and the secondary outcomes were mean adherence during 1 to 12 months of follow-up, change in SSQ-14 and Patient Health Questionnaire (PHQ-9) scores (3, 6, 9, and 12 months), and viral load suppression (6 and 12 months). A total of 516 participants were recruited (244 in Friendship Bench and 272 in enhanced standard care facilities); 438 (84.9%) were female and the mean (SD) age was 45.6 (10.9) years. Mean (SD) adherence between 2 to 6 months was 89.9% (18.4%) in the Friendship Bench group and 87.2% (20.1%) in the control group. The intervention had no statistically significant effect on adherence between 2 to 6 months (unadjusted mean difference, 1.93 percentage points; 95% CI, -1.20 to 5.06 percentage points; P = .23), between months 1 to 12 (mean difference 0.79 percentage points; 95% CI, -2.14 to 3.71 percentage points; P = .60), or viral suppression. Declines in SSQ-14 scores from baseline to 3 months (difference, -1.65; 95% CI, -3.07 to -0.24), 6 months (difference, -1.57; 95% CI, -2.98 to -0.15), and 9 months (difference, -1.63; 95% CI, -3.05 to -0.22) were greater in the Friendship Bench than the standard care group (P < .05). There were no differences in the decline in the SSQ-14 scores from baseline to 12 months and in declines in PHQ-9 scores from baseline to 3, 6, 9, and 12 months. In this randomized trial of HIV-positive participants with CMD, the Friendship Bench intervention had no effect on adherence and viral suppression, possibly due to the absence of skill-based adherence training and a ceiling effect. ClinicalTrials.gov Identifier: NCT03704805.

Identifiants

pubmed: 37440230
pii: 2807191
doi: 10.1001/jamanetworkopen.2023.23205
pmc: PMC10346120
doi:

Substances chimiques

Anti-Retroviral Agents 0

Banques de données

ClinicalTrials.gov
['NCT03704805']

Types de publication

Randomized Controlled Trial Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e2323205

Investigateurs

Amos Kateta (A)
Cuthbert Mutonhodza (C)
Favourite Machiha (F)
Ntandoyenkosi Mhlanga (N)
Shingai Matutururu (S)
Tatenda Gombwiro (T)
Millicent Gweredza (M)
Josephine Yasmin Saide (JY)
Beauty Muchakubvura (B)
Kudzai Mhlanga (K)
Dennis Mwakasa (D)
Fungai Nyikadzino Zvekare (FN)
Yvonne Chiedza Maumbe (YC)
Boldwin Maposa (B)
Sibongile Gumbo (S)
Japhet Kamusha (J)
Morris Tshuma (M)
Rejoyce Runyowa (R)
Abigail Pikayi (A)
Fredrick Mbiba (F)
Chiedza Elizabeth Mutungama (CE)
Waraidzo Am Mukuwapasi (WA)
Rudo Mandabva (R)
Sven Trelle (S)
Ethel Manda (E)
Duncan Tatenda Majichi (DT)

Commentaires et corrections

Type : UpdateOf

Références

Lancet HIV. 2016 Nov;3(11):e529-e538
pubmed: 27658881
Acta Psychiatr Scand. 1997 Jun;95(6):469-75
pubmed: 9242841
AIDS. 2021 Oct 1;35(12):2017-2024
pubmed: 34172673
Ann Behav Med. 2014 Jun;47(3):259-69
pubmed: 24234601
BMJ Open. 2020 May 15;10(5):e035246
pubmed: 32414825
AIDS Behav. 2023 Jun;27(6):1849-1861
pubmed: 36592251
J Acquir Immune Defic Syndr. 2016 Jan 1;71(1):38-46
pubmed: 26761270
Lancet Glob Health. 2020 Oct;8(10):e1326-e1334
pubmed: 32971055
Epidemiol Psychiatr Sci. 2021 May 17;30:e37
pubmed: 33993900
J Gen Intern Med. 2001 Sep;16(9):606-13
pubmed: 11556941
Bull World Health Organ. 2004 Nov;82(11):858-66
pubmed: 15640922
Arch Intern Med. 1998 Sep 14;158(16):1789-95
pubmed: 9738608
Cochrane Database Syst Rev. 2017 Mar 14;3:CD010806
pubmed: 28291302
J Int AIDS Soc. 2020 Dec;23(12):e25644
pubmed: 33283916
Health Psychol. 2018 Jun;37(6):574-585
pubmed: 29781655
Brain Behav Immun. 2018 Oct;73:261-273
pubmed: 29768184
AIDS Behav. 2021 Oct;25(10):3097-3105
pubmed: 33598866
Lancet. 2007 Sep 8;370(9590):859-77
pubmed: 17804063
JAMA. 2016 Dec 27;316(24):2618-2626
pubmed: 28027368
BMJ Open. 2021 Jul 7;11(7):e049824
pubmed: 34233999
Int J Ment Health Syst. 2015 May 23;9:21
pubmed: 27408619
J Int AIDS Soc. 2018 Feb;21(2):
pubmed: 29479867
PLoS One. 2010 May 05;5(5):e10460
pubmed: 20485480
AIDS Behav. 2018 Jan;22(1):9-42
pubmed: 28361453
AIDS Behav. 2019 Aug;23(8):2059-2071
pubmed: 30659424
PLoS One. 2017 Aug 4;12(8):e0181960
pubmed: 28783739
J Affect Disord. 2016 Jul 1;198:50-5
pubmed: 27011359
AIDS Behav. 2018 Jan;22(1):86-101
pubmed: 28063075
AIDS Behav. 2012 Nov;16(8):2101-18
pubmed: 22116638
AIDS Behav. 2021 Oct;25(10):3047-3056
pubmed: 33880670
Clin Psychol Rev. 2017 Feb;51:164-184
pubmed: 27939443
Curr HIV/AIDS Rep. 2014 Sep;11(3):291-307
pubmed: 25038748
PLoS Med. 2013;10(4):e1001418
pubmed: 23585736
Psychol Health Med. 2019 Jun;24(5):578-594
pubmed: 30479159
PLoS Med. 2022 Jan 5;19(1):e1003887
pubmed: 34986170
J Int AIDS Soc. 2021 Oct;24(10):e25823
pubmed: 34708929

Auteurs

Andreas D Haas (AD)

Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.

Cordelia Kunzekwenyika (C)

SolidarMed, Masvingo, Zimbabwe.

Josphat Manzero (J)

SolidarMed, Masvingo, Zimbabwe.

Stefanie Hossmann (S)

Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.

Andreas Limacher (A)

Clinical Trials Unit Bern, University of Bern, Bern, Switzerland.

Janneke H van Dijk (JH)

SolidarMed, Masvingo, Zimbabwe.

Ronald Manhibi (R)

SolidarMed, Masvingo, Zimbabwe.

Per von Groote (P)

Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.

Michael A Hobbins (MA)

SolidarMed, Luzern, Switzerland.

Ruth Verhey (R)

Friendship Bench, Harare, Zimbabwe.

Matthias Egger (M)

Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.
Centre for Infectious Disease Epidemiology and Research, University of Cape Town, Cape Town, South Africa.
Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH